In line with the immunosuppressive role of β1,6-branched glycans, CCL2 secreted by cancer cells contributes to an immunosuppressive tumor microenvironment, and blockade of CCR2 in mice improved the efficacy of immune checkpoint therapy (Matsuo et al., 2021; Tu et al., 2020), suggesting a direct biomedically relevant role of this glycan feature. This evidence concerns the gene CCL2 and cancer.